Skip to content 
Search

Latest Stories

Cannabis-based pain treatment firm Oxford Cannabinoid Technologies to list in London

A cannabis-based pain treatment company, controlled by Neil Mahapatra and Gavin Sathianathan, will start trading on the London Stock Exchange on Friday (21).

Oxford Cannabinoid Technologies (OCT), backed by Snoop Dogg and Imperial Brands, raised £16.5 million in a placing that values the company at about £50 million recently, reported The Times.


After the listing, almost 21 per cent of the company will be owned by Kingsley Capital Partners, controlled by Mahapatra, OCT’s co-founder and executive chairman, and eight per cent by Sathianathan, is co-founder, and his wife, the report added.

Imperial Brands will have a holding of almost 11 per cent, while Casa Verde will own just over two per cent. Snoop Dogg, a partner with Casa Verde, had an investment of $10m in the company.

Bishrut Mukherjee and Karan Dharam Wadhera are directors in the firm.

The business was founded in 2017 to develop prescription medicines derived from cannabis and has a research partnership with Oxford University. Casa Verde, the cannabis-focused venture capital firm that counts Dogg, the rapper, among its partners, invested $10m in 2018. Imperial Brands, the tobacco group, invested in the same funding round, The Times report added.

Cairn Financial Advisers and States Bridge Capital are advising on the listing, which will be a standard rather than a premium listing, the report said.

The company said that it aimed to commercialise its first drug by 2027 and intended to 'develop a portfolio of four drug candidates for approval as licensed pain medicines'. It estimated that the 'addressable pain market' was worth at least £42.5 billion globally.

OCT’s leading drug candidate — OCT461201 — is being developed as a solid oral medicine that is in pre-clinical testing. It aims to carry out early stage clinical trials to treat irritable bowel syndrome and post-herpetic neuralgia, a complication of shingles, The Times report added.

In February GW Pharmaceuticals, the British company that was the first to secure regulatory approval for a cannabis-based treatment in America, was bought for $7.2 billion by Jazz, a larger rival.

It developed Epidiolex, a treatment for epilepsy using cannabidiol, a part of the plant that does not make you high, and had sales of more than $500m of the drug last year.

More For You

Bangladesh seeks US deal to shield garment industry from tariffs

Workers are engaged at their sewing stations in a garment factory in Savar, on the outskirts of Dhaka, on April 9, 2025. (Photo by MUNIR UZ ZAMAN/AFP via Getty Images)

Bangladesh seeks US deal to shield garment industry from tariffs

BANGLADESH, the world's second-biggest garment manufacturer, aims to strike a trade deal with the US before Donald Trump's punishing tariffs kick in next week, said the country's top commerce official.

Dhaka is proposing to buy Boeing planes and boost imports of US wheat, cotton and oil in a bid to reduce the trade deficit, which Trump used as the reason for imposing painful levies in his "Liberation Day" announcement.

Keep ReadingShow less
UK business district
The Canary Wharf business district including global financial institutions in London.
Getty Images

Bond yields ease following Starmer’s support for Reeves

THE COST of UK government borrowing fell on Thursday, partially reversing the rise seen after Chancellor Rachel Reeves became emotional during Prime Minister’s Questions.

The yield on 10-year government bonds dropped to 4.55 per cent, down from 4.61 per cent the previous day. The pound also recovered slightly to $1.3668 (around £1.00), though it did not regain all its earlier losses.

Keep ReadingShow less
modi-trump-getty
Modi shakes hands with Trump before a meeting at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)
Getty Images

Indian exporters watch closely as Trump says trade deal with India likely

THE US could reach a trade deal with India that would help American companies compete more easily in the Indian market and reduce tariff rates, President Donald Trump said on Tuesday. However, he cast doubt on a similar deal with Japan.

Speaking to reporters on Air Force One, Trump said he believed India was ready to lower trade barriers, potentially paving the way for an agreement that would avoid the 26 per cent tariff rate he had announced on April 2 and paused until July 9.

Keep ReadingShow less
Kolhapuri sandal sales surge in India post Prada controversy

Customers shop for 'Kolhapuri' sandals, an Indian ethnic footwear, at a store in New Delhi, India, June 27, 2025. REUTERS/Adnan Abidi

Kolhapuri sandal sales surge in India post Prada controversy

INDIAN footwear sellers and artisans are tapping into nationalist pride stoked by the Prada 'sandal scandal' in a bid to boost sales of ethnic slippers with history dating back to the 12th century, raising hopes of reviving a struggling craft.

Sales are surging over the past week for the 'Kolhapuri' sandals that have garnered global attention after Prada sparked a controversy by showcasing similar designs in Milan, without initially crediting the footwear's origins.

Keep ReadingShow less
UK business district
The Canary Wharf business district including global financial institutions in London.
Getty Images

Economy grew 0.7 per cent in Q1 2025, fastest in a year

THE UK economy expanded at its fastest pace in a year during the first quarter of 2025, driven by a rise in home purchases ahead of a tax deadline and higher manufacturing output before the introduction of new US import tariffs.

Gross domestic product rose by 0.7 per cent in the January-to-March period, the Office for National Statistics (ONS) said, confirming its earlier estimate. This was the strongest quarterly growth since the first quarter of 2024.

Keep ReadingShow less